(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 246.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.33%.
Humacyte's revenue in 2026 is $2,396,000.On average, 7 Wall Street analysts forecast HUMA's revenue for 2026 to be $992,572,629, with the lowest HUMA revenue forecast at $571,708,500, and the highest HUMA revenue forecast at $1,513,999,672. On average, 7 Wall Street analysts forecast HUMA's revenue for 2027 to be $6,157,394,997, with the lowest HUMA revenue forecast at $2,885,766,715, and the highest HUMA revenue forecast at $12,630,090,844.
In 2028, HUMA is forecast to generate $31,535,640,880 in revenue, with the lowest revenue forecast at $12,931,501,788 and the highest revenue forecast at $50,287,012,967.